Actively Recruiting
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
Led by University of Michigan Rogel Cancer Center · Updated on 2026-01-16
136
Participants Needed
1
Research Sites
415 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectomy radiation therapy (also known as stereotactic body radiation therapy \[SBRT\]) versus the self-reported QOL of those treated with moderately hypo-fractionated post-prostatectomy radiation (a current standard of care option).
CONDITIONS
Official Title
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men age 6 18 with confirmed prostate cancer after radical prostatectomy with a PSA 6 0.1 ng/mL
- At least 6 months between prostatectomy and planned radiation therapy start
- Karnofsky Performance Status (KPS) of 70 or higher
- Equivocal pelvic lymph nodes 6 1.5 cm in short axis allowed
- Ability to complete the EPIC-26 quality of life questionnaire
- Ability to provide tissue from radical prostatectomy for pathology review
- Ability to understand and willing to sign informed consent
You will not qualify if you...
- Prior pelvic radiation therapy
- History of moderate/severe or active Crohn's disease or ulcerative colitis
- History of bladder neck or urethral stricture
- Evidence of distant metastatic disease or nodal involvement beyond common iliac vessels
- Androgen deprivation therapy started more than 6 months before enrollment or use of non-LHRH/GnRH agents
- History of another invasive cancer within past 3 years except treated skin cancer
- Any condition that would prevent participation as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States, 98107
Actively Recruiting
Research Team
C
Cancer AnswerLine
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here